AI assistant
H. Lundbeck A — Director's Dealing 2013
Feb 22, 2013
Preview isn't available for this file type.
Download source fileH. Lundbeck A/S hereby reports transactions made by executives and persons and
legal entities closely associated to them with shares in H. Lundbeck A/S and
linked securities, cf. section 28a of the Danish Securities Trading Act.
The list is based on reports received by H. Lundbeck A/S from the company's
executives today or yesterday.
Name: Melanie Georgina Lee
Job position of the executive: Board member
ID code (ISIN code): DK 0010287234
Description of the security: Share
Nature of the transaction: Purchase of shares
Date of trading: 21 February 2013
Market on which the trading was effected: Nasdaq OMX Copenhagen
Number of traded securities: 900 shares
Market price of securities traded: DKK 84,287.34
Persons or entities under an obligation to report are defined as members of the
Executive Management and the Supervisory Board of H. Lundbeck A/S and
persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
-- spouse or cohabitant
-- children below the age of 18
-- legal entities in which the insider has a controlling influence
Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial guidance for 2013, which was provided on 6 February 2013 in
connection with the release of the financial results for 2012.
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Simon Mehl Augustesen
Chief Specialist, Head of Investor Relations International Media Specialist
[email protected] [email protected]
+45 36 43 24 26 +45 36 43 49 80
About Lundbeck
Lundbeck is a global pharmaceutical company highly committed to improving the
quality of life of people living with brain diseases. For this purpose,
Lundbeck is engaged in the entire value chain throughout research, development,
production, marketing and sales of pharmaceuticals across the world. The
company’s products are targeted at disorders such as depression and anxiety,
psychotic disorders, epilepsy, Huntington’s, Alzheimer’s and Parkinson’s
diseases. Lundbeck’s pipeline consists of several mid- to late- stage
development programs.
Lundbeck employs more than 5800 people worldwide, 2,000 of whom are based in
Denmark. We have employees in 57 countries, and our products are registered in
more than 100 countries. We have research centers in Denmark, China and the
United States and production facilities in Italy, France, Mexico, China and
Denmark. Lundbeck generated revenue of approximately DKK 15 billion in 2012.
For additional information, we encourage you to visit our corporate site
www.lundbeck.com.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our
expectations or forecasts of future events such as new product introductions,
product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and
inaccurate assumptions. This may cause actual results to differ materially from
expectations and it may cause any or all of our forward-looking statements here
or in other publications to be wrong. Factors that may affect future results
include interest rate and currency exchange rate fluctuations, delay or failure
of development projects, production problems, unexpected contract breaches or
terminations, government-mandated or market-driven price decreases for
Lundbeck's products, introduction of competing products, Lundbeck's ability to
successfully market both new and existing products, exposure to product
liability and other lawsuits, changes in reimbursement rules and governmental
laws and related interpretation thereof, and unexpected growth in costs and
expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for
full disclosure of material corporate information. Some assumptions, including
assumptions relating to sales associated with product that is prescribed for
unapproved uses, are made taking into account past performances of other
similar drugs for similar disease states or past performance of the same drug
in other regions where the product is currently marketed. It is important to
note that although physicians may, as part of their freedom to practice
medicine in the US, prescribe approved drugs for any use they deem appropriate,
including unapproved uses, at Lundbeck, promotion of unapproved uses is
strictly prohibited.